This is an old revision of this page, as edited by Mo18ekula (talk | contribs) at 14:15, 19 December 2024 (←Created page with '{{Infobox drug | drug_name = Mcn 5707 | image = Mcn 5707.svg | width = 250px | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = | class = | ATC_prefix = | ATC_suffix = <!-- Legal status --> | legal_status = <!-- Pharmaco...'). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:15, 19 December 2024 by Mo18ekula (talk | contribs) (←Created page with '{{Infobox drug | drug_name = Mcn 5707 | image = Mcn 5707.svg | width = 250px | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = | class = | ATC_prefix = | ATC_suffix = <!-- Legal status --> | legal_status = <!-- Pharmaco...')(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundIdentifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H18ClN |
Molar mass | 283.80 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Mcn 5707 is a SNDRI agent for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980’s.
The Ki numbers quoted (24b) are: DAT 35.9nM, NET: 1.9nM and SERT = 8.5nM.
Ref:
References
- Maryanoff, B. E., Shank, R. P., Gardocki, J. F. (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
- Maryanoff, BE; et al.; Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J Med Chem 1984, 27, 8, 943.
- Bruce E. Maryanoff, US4719216 (1988 to Janssen Pharmaceuticals Inc).
References
Stimulants | |
---|---|
Adamantanes | |
Adenosine antagonists | |
Alkylamines | |
Ampakines | |
Arylcyclohexylamines | |
Benzazepines | |
Cathinones |
|
Cholinergics |
|
Convulsants | |
Eugeroics | |
Oxazolines | |
Phenethylamines |
|
Phenylmorpholines | |
Piperazines | |
Piperidines |
|
Pyrrolidines | |
Racetams | |
Tropanes |
|
Tryptamines | |
Others |
|
ATC code: N06B |
Monoamine reuptake inhibitors | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |